integument
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis
|
dermatitis
(
J:100506
)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils
• however, inflammation is not seen in the small intestine or colon
|
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis
|
acanthosis
(
J:100506
)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis
|
reddish skin
(
J:100506
)
• seen in dox treated mutants
|
skin lesions
(
J:100506
)
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back
• less commonly, lesions are seen on the anterior neck and hind legs
|
immune system
• dox treated mutants exhibit splenomegaly
|
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes
|
• in dox treated mutants
|
• in dox treated mutants
|
• in dox treated mutants
|
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin
|
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes
|
• dox treated mutants exhibit lymphadenopathy
|
• a few dox treated mice exhibit conjunctivitis
|
dermatitis
(
J:100506
)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils
• however, inflammation is not seen in the small intestine or colon
|
hematopoietic system
• dox treated mutants exhibit splenomegaly
|
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes
|
• in dox treated mutants
|
• in dox treated mutants
|
• in dox treated mutants
|
homeostasis/metabolism
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis
|
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin
|
vision/eye
• a few dox treated mice exhibit conjunctivitis
|
growth/size/body
• dox treated mutants exhibit splenomegaly
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
atopic dermatitis | DOID:3310 |
OMIM:603165 OMIM:PS603165 |
J:100506 |